Omar Saeed, MD
Internal Medicine · Bronx, NYNPI 1104003292
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,515 of the $7,485 with a category attached, or 73.7%. Abbott accounts for 66.2% of it on its own, with 18 other manufacturers making up the rest. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $57.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Abiomed$832
- Merck$313
- Ancora Heart, Inc.$303
- Cvrx, Inc.$180
- Pfizer$147
- plus $758 from 13 others
Across 55 payments — averaging $2924.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$124K
- Radiometer America, Inc$37K
What the payments were for
- Travel & lodging$1,97026%
- Food & beverage$5,51574%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 64 | $4,952 |
| Abiomed | 8 | $832 |
| Merck | 18 | $313 |
| Ancora Heart, Inc. | 1 | $303 |
| Cvrx, Inc. | 2 | $180 |
| Pfizer | 8 | $147 |
| Medtronic | 1 | $118 |
| Novartis | 5 | $107 |
| Actelion Pharmaceuticals US, Inc. | 4 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $95 |
| Scpharmaceuticals Inc. | 3 | $61 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $58 |
| Philips North America LLC | 2 | $51 |
| AstraZeneca | 2 | $44 |
| Endotronix, Inc. | 1 | $28 |
| Bridgebio Pharma, Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Bristol Myers Squibb | 1 | $21 |
| Amgen | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,485 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 111 | $95,985 |
| JardianceEmpagliflozin | 30 | $26,880 |
| EliquisApixaban | 35 | $21,206 |
| FarxigaDapagliflozin Propanediol | 18 | $16,746 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $4,132 |
| Varenicline Tartrate | 12 | $3,102 |
| Metoprolol Succinate | 90 | $1,313 |
| Atorvastatin Calcium | 78 | $718 |
| Torsemide | 31 | $602 |
| Spironolactone | 83 | $448 |
| Carvedilol | 45 | $442 |
| Hydralazine Hcl | 19 | $359 |
| Metolazone | 12 | $317 |
| Digoxin | 24 | $280 |
| Amiodarone Hcl | 21 | $232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $107 | $95,985111 claims |
| PfizerEliquis | $147 | $21,20635 claims |
| AstraZenecaFarxiga | $44 | $16,74618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bronx
- Jason LeiderBronx$694K
- Bulent AtacBronx$647K
- Timothy KanterBronx$630K
- Shervin MortazaviBronx$374K
- Elizabeth Jenny-AvitalBronx$185K
- Meyer HalberstamBronx$143K
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.